Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaBench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.Antibiotic stewardship in the intensive care unit.Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against gram-negative bacteria collected from Shenyang, China.Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatmentPseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors.Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysisAppraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies.Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumoniaEffects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin.Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomesImpact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay.Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremiaDevelopment and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patientsClinical outcomes of type III Pseudomonas aeruginosa bacteremia.Severe Pseudomonas aeruginosa infections. Tackling the conundrum of drug resistance.Combination therapy for treatment of infections with gram-negative bacteria.Management of severe bacterial infections.Polymicrobial Ventilator-Associated Pneumonia: Fighting In Vitro Candida albicans-Pseudomonas aeruginosa Biofilms with Antifungal-Antibacterial Combination Therapy.Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.Does antibiotic selection impact patient outcome?A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients.Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.Incidence of Pseudomonas aeruginosa bacteremia: a population-based studyBeta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli.Morbidity associated with Pseudomonas aeruginosa bloodstream infections.Prevalence of antimicrobial-resistant bacteria isolated from older versus younger hospitalized adults: results of a two-centre study.Pseudomonas skin infection: clinical features, epidemiology, and management.Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms.Prevention and management of central line-associated bloodstream infections in hospital practice.Pseudomonas aeruginosa treatment and transmission reduction.Combination therapy for Gram-negative bacteria: what is the evidence?Safety and feasibility of antibiotic de-escalation in bacteremic pneumonia.In vitro activities of tritrpticin alone and in combination with other antimicrobial agents against Pseudomonas aeruginosa.
P2860
Q24612271-1DD70BE3-10FC-4F8E-953F-E7D57D97597CQ24813204-9612D8D2-F788-4F8F-8EF8-E20D38307BC0Q30408712-3BE35C20-7413-4CA4-8D4A-E8168E1C870FQ33236778-EB8B095A-9507-4454-B809-9339D4FD531BQ33603799-6B200CE9-0F59-4101-B026-2C9D14A9B67EQ33722082-9BB48AF8-698E-46CA-A9E7-E82A1A4D9450Q33732032-25E1B07A-B0B8-48B4-954A-CC1A3ACAFEBAQ33826400-C7988431-73D7-44AD-B447-BD93F8AC871CQ34003193-E679EFBF-53FE-453E-8F3C-9E5A05059C0CQ34064473-3976556B-90C4-4B5B-AB0F-E55C7607F6ACQ34418911-75CDCCD7-7A18-4E96-A1FC-9E2AB12E755AQ34479844-A3E0A6F9-261B-4296-8E0E-59BFCD3057F3Q34694922-ECE5B567-1AF8-448E-8C5A-E70FEF31D3FBQ34766191-E728C123-74E2-476D-A684-5AC44FD59CD8Q35091494-A4FBF6AE-7BE5-45B2-A268-C3F66B71A68AQ35127299-E4B3CC42-9A3E-446B-A748-3DE6B8B4E9CDQ35647791-6311BB51-5D9A-44F6-9073-CA6DD3F0406EQ35758992-AD88F8BD-AE9E-4F4C-8E94-DE5D71E2AFE7Q35783999-2865B321-34E5-4E70-AA99-05B0FF913E50Q36021050-0D8F7C19-09E2-42B2-B5AB-EECF8B509346Q36156077-49B7F30F-B2B7-4E9B-83AB-E536DD171CDEQ36233511-99BBD63A-F3BC-4B03-90CF-02B464EA329AQ36257537-B881B743-AD64-465B-90AC-C3F8C4B02067Q36667202-7FBA5E30-FA0C-4403-8714-8487DB6B8A13Q36672883-4115A6E1-CE8B-4870-BCDF-897F14C32C0AQ36864125-B6F778BF-66ED-4622-A10D-60ED47B1A604Q37036553-28AF95B5-BC9A-4037-B620-4300D3CB8D16Q37041262-2A7DA5EA-523E-4B3A-AF37-20B9C34ADE22Q37144870-672A24F5-934B-4679-9214-183301E49D5AQ37219943-99BA26ED-9057-4F5A-8A3D-05E3F017C0CAQ37417508-AA7E5C54-ECFB-4C56-8272-3523A6E5D088Q37862227-37B2B561-1367-4A28-A9A1-B1EB3CBD5F49Q37933370-E306EB90-D739-42E0-8C66-921E005EE61BQ37949391-D51273E8-54F9-49E6-90C4-75C80CC47B80Q37954711-8E9A05FB-3B72-4414-807F-32951FB21959Q37992486-E17AE884-8F3D-4244-805A-FC68B00B605CQ38131538-96C2B3CE-D4CC-4D7F-92C8-656B16A298FFQ38156194-6D577EF5-78C1-494F-9A01-1F602EABE10DQ38233861-D1AA092F-011F-42D0-8AC0-8AE0B9644E5DQ39077770-184AEF06-CE69-43AF-BC00-D07699237008
P2860
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
@ast
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
@en
type
label
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
@ast
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
@en
prefLabel
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
@ast
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
@en
P2093
P2860
P1476
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
@en
P2093
Christian Van Delden
Emmanuelle Boffi El Amari
Eric Chamot
Peter Rohner
P2860
P304
P356
10.1128/AAC.47.9.2756-2764.2003
P407
P577
2003-09-01T00:00:00Z